Compare · PROF vs RMD
PROF vs RMD
Side-by-side comparison of Profound Medical Corp. (PROF) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PROF and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 137.2x PROF ($248.8M).
- Both names hit the wire about 9 times in the past 4 weeks.
- RMD has more recent analyst coverage (25 ratings vs 8 for PROF).
- Company
- Profound Medical Corp.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $248.8M
- $34.13B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 9
- Recent ratings
- 8
- 25
Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PROF
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’
- Profound Medical Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical Announces Management Change
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
- SEC Form 10-Q filed by Profound Medical Corp.
- Profound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Profound Medical Reports Second Quarter 2026 Financial Results
- Profound Medical upgraded by Raymond James with a new price target
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)